- Trials with a EudraCT protocol (113)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
113 result(s) found for: Small intestine.
Displaying page 5 of 6.
EudraCT Number: 2018-003304-39 | Sponsor Protocol Number: 007 | Start Date*: 2019-01-23 | ||||||||||||||||
Sponsor Name:Morten Rasmussen | ||||||||||||||||||
Full Title: Efficacy of a novel 1l PEG plus ascorbate (Plenvu) bowel preparation vs. 2l PEG plus ascorbate (Moviprep), a randomized controlled multicenter trial | ||||||||||||||||||
Medical condition: Bowel preparation before colonoscopy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-002542-38 | Sponsor Protocol Number: CAEB071A2210 | Start Date*: 2007-11-28 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis. | |||||||||||||
Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002924-17 | Sponsor Protocol Number: A3384-001 | Start Date*: 2014-01-27 |
Sponsor Name:Albireo AB | ||
Full Title: A double-blind, randomized, placebo-controlled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsor... | ||
Medical condition: Patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-004394-14 | Sponsor Protocol Number: ZP1848-17111 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS) | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) DK (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015158-39 | Sponsor Protocol Number: SAG-51/DIV | Start Date*: 2010-05-06 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, dose-response, randomised, placebo-controlled, parallel group, multicentre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevent... | |||||||||||||
Medical condition: Diverticulitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002486-21 | Sponsor Protocol Number: GLY-311-2017 | Start Date*: 2018-01-18 | |||||||||||
Sponsor Name:GLyPharma Therapeutic, Inc. (a wholly owned subsidiary of VectivBio Holding AG) | |||||||||||||
Full Title: A once weekly, repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and pharmacodynamics of FE 203799 in patients with short bowel syndrome wi... | |||||||||||||
Medical condition: Short Bowel Syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001688-22 | Sponsor Protocol Number: 01CCRe-IV | Start Date*: 2013-08-23 | |||||||||||
Sponsor Name:Servicio de Cirugía General y Digestiva Hospital Universitario de Bellvitge | |||||||||||||
Full Title: Randomized multicenter trial in colorectal cancer patients with non-resectable metastasis. Impact of tumor resection versus chemotherapy alone in survival. | |||||||||||||
Medical condition: Cancer colorectal stage IV with synchronous non-resectable metastasis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004370-14 | Sponsor Protocol Number: 20150930 | Start Date*: 2016-07-07 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: 89Zr-AMG211 PET imaging in patients with relapsed/refractory gastrointestinal adenocarcinoma before and during treatment with AMG 211 | ||
Medical condition: Relapsed/refractory gastrointestinal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004375-12 | Sponsor Protocol Number: TODINELI | Start Date*: 2014-02-13 | |||||||||||||||||||||
Sponsor Name:Center of Mech-Sense | |||||||||||||||||||||||
Full Title: TODINELI Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of the neuroprotective effect of Liraglutide for treatment of diabetic neuropathy | |||||||||||||||||||||||
Medical condition: TODINELI Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of the neuroprotective effect of Liraglutide for treatment of diabetic neuropathy i... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005454-35 | Sponsor Protocol Number: RG_15-235 | Start Date*: 2016-09-23 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD) | |||||||||||||
Medical condition: Post-transplant lymphoproliferative disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004797-18 | Sponsor Protocol Number: | Start Date*: 2017-06-26 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients. | |||||||||||||
Medical condition: Intestinal failure with an underlying aetiology of short bowel | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004479-11 | Sponsor Protocol Number: DPTLDSG-IIT-PTLD-2 | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:DIAKO Ev. Diakonie-Krankenhaus Bremen gGmbH | |||||||||||||
Full Title: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined W... | |||||||||||||
Medical condition: Previously untreated CD20-positive lymphoproliferative disorder (PTLD) following solid organ transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000331-14 | Sponsor Protocol Number: ICORG 05-02/NSABP C-08 | Start Date*: 2005-04-08 |
Sponsor Name:All Ireland Cooperative Oncology Research Group | ||
Full Title: A phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX -6) every 2 weeks with Bevacizumab to the same regimen without Bevacizumab for the treatme... | ||
Medical condition: Resected stage II or stage III adenocarcinoma of the colon | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000102-25 | Sponsor Protocol Number: ALXN1840-WD-Cu-Excretion | Start Date*: 2021-04-09 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Efficacy of ALXN1840 on human biliary copper excretion quantified with 64CuCl2 PET/MR-scan | |||||||||||||
Medical condition: Wilson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003205-29 | Sponsor Protocol Number: CAP2022-1 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Aphaia Pharma US LLC | |||||||||||||
Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path... | |||||||||||||
Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002517-18 | Sponsor Protocol Number: PROICM2020-04GAB | Start Date*: 2020-10-19 | |||||||||||
Sponsor Name:Institut régional du cancer de Montpellier (ICM) | |||||||||||||
Full Title: Phase II study evaluating the benefit of sequential treatment with Gemcitabine/Nab-Paclitaxel (Gembrax) then Folfirinox followed by adaptative MRI-guided stereotactic radiotherapy in patients with ... | |||||||||||||
Medical condition: Locally advanced adenocarcinoma of pancreas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001306-30 | Sponsor Protocol Number: PROICM2021-04REL | Start Date*: 2021-09-13 | |||||||||||
Sponsor Name:Institut Régional du Cancer de Montpellier | |||||||||||||
Full Title: A prospective randomized phase II study to assess the schemas of retreatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with new progression of intestinal well-differentiated neuroendocrine ... | |||||||||||||
Medical condition: Patients with new progression of intestinal well-differentiated neuroendocrine tumor. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002668-28 | Sponsor Protocol Number: HP-301 | Start Date*: 2020-04-21 | |||||||||||
Sponsor Name:Phathom Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared t... | |||||||||||||
Medical condition: Helicobacter pylori infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003509-13 | Sponsor Protocol Number: MLN0002-3028 | Start Date*: 2015-05-15 |
Sponsor Name:Takeda Development Centre Europe Ltd | ||
Full Title: An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV | ||
Medical condition: Crohn's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002556-77 | Sponsor Protocol Number: MT-1303-E13 | Start Date*: 2014-11-27 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC) | |||||||||||||
Full Title: A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Act... | |||||||||||||
Medical condition: Subjects with moderate to severe crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) NL (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
